US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1886 Views
-
Last post by frodo
-
- 0 Replies
- 1231 Views
-
Last post by NHE
-
- 0 Replies
- 1680 Views
-
Last post by frodo
-
- 0 Replies
- 1226 Views
-
Last post by frodo
-
- 1 Replies
- 1723 Views
-
Last post by frodo
-
- 0 Replies
- 2023 Views
-
Last post by NHE
-
- 0 Replies
- 2348 Views
-
Last post by NHE
-
- 0 Replies
- 1066 Views
-
Last post by frodo
-
- 1 Replies
- 1430 Views
-
Last post by NHE